Generic Visicol Availability
Visicol is a brand name of sodium biphosphate/sodium phosphate, approved by the FDA in the following formulation(s):
VISICOL (sodium phosphate, dibasic anhydrous; sodium phosphate, monobasic, monohydrate - tablet; oral)
-
Manufacturer: SALIX PHARMS
Approval date: September 21, 2000
Strength(s): 0.398GM;1.102GM [RLD]
Has a generic version of Visicol been approved?
No. There is currently no therapeutically equivalent version of Visicol available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Visicol. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Non-aqueous colonic purgative formulations
Patent 5,616,346
Issued: April 1, 1997
Inventor(s): Aronchick; Craig A.
Orally administered colonic purgative formulations and methods of its use for effecting partial or complete purgation of the colon in mammals, the formulations consisting of non-aqueous admixtures of monobasic, dibasic and tribasic sodium phosphates administered in tablet or capsule form in concentrations of from 0.01 to 0.85 grams per kilogram body weight. Preferred embodiments include the addition of binders, dispersants and buffers which do not adversely affect osmolality or effectiveness of the purgative formulations.Patent expiration dates:- May 18, 2013✓
- May 18, 2013
See also...
- Visicol Consumer Information (Wolters Kluwer)
- Visicol Consumer Information (Cerner Multum)
- Fleet enema Consumer Information (Wolters Kluwer)
- Sodium phosphates Consumer Information (Wolters Kluwer)
- Sodium phosphates enema Consumer Information (Wolters Kluwer)
- Sodium phosphates solution Consumer Information (Wolters Kluwer)
- Sodium biphosphate and sodium phosphate Consumer Information (Cerner Multum)
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
